If a drug blocks the reuptake transporter for dopamine in the synapse of the nigrostriatal pathway, which consequence follows for dopamine signaling?

💡 Explanation

Blocking the reuptake transporter increases dopamine concentration and its duration of action in the synaptic cleft because dopamine remains available to bind to receptors for a longer period, therefore increasing postsynaptic signaling, rather than decreasing synthesis or directly affecting receptors.

• Why does two-point discrimination acuity vary across the skin surface?
• Why does vaccine efficacy often increase after multiple doses, even with the same antigen?
• Why does excessive omega-6 fatty acid intake increase the risk of chronic inflammatory diseases, impairing inflammation resolution?
• If a burn injury damages the reticular dermis, why does long-term skin regeneration often result in hypertrophic scarring rather than complete restoration?
• If a macrophage is unable to effectively clear apoptotic cells during inflammation resolution, which consequence is most likely?
• A long-distance runner increases their training volume rapidly. Which risk increases as bone strain increases in the tibia during this rapid adaptation?